Skip to main
BIO
BIO logo

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories demonstrates a solid financial outlook driven by its diverse revenue streams, with clinical diagnostics accounting for 60% of sales and life sciences contributing 40%, securing a strong position in both markets. The company is expected to benefit from ongoing ERP efficiencies, which are anticipated to enhance margins and improve operational effectiveness. Furthermore, analysts foresee a reversal of current pressures as macroeconomic conditions stabilize, alongside the expectation of continued strategic execution towards FY’25 targets, which could positively impact overall financial multiples.

Bears say

Bio-Rad Laboratories has issued new revenue guidance indicating a projected decline of approximately $40 million, or 40%, in sales to federally funded academic and government customers, which is markedly more conservative compared to peers like Thermo Fisher Scientific and Avantor. The company has also lowered its full-year top-line revenue and margin expectations by about 200 basis points each, despite achieving a beat in Q1 2025. Additionally, there are concerns regarding a potential demand slowdown influenced by macroeconomic conditions, which have not been adequately addressed by management compared to its competitors.

Bio-Rad Laboratories (BIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Buy based on their latest research and market trends.

According to 4 analysts, Bio-Rad Laboratories (BIO) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $333.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $333.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.